DENVER, May 5, 2020 / PRNewswire / – As part of its ongoing efforts to further transform patient care, DaVita unveiled today DaVita Company Group (DVG). This group plans to accelerate DaVita’s efforts to develop and deploy solutions designed to improve healthcare and quality of life for people with kidney disease and related chronic diseases.
“Innovation should never stop when it is possible to improve patient care,” said Javier Rodriguez, CEO of DaVita. “We want to transform kidney health – from chronic kidney disease to transplantation – and we are devoting financial and strategic resources to these solutions. We believe we can be the partner of choice for entrepreneurs who want to bring the best technologies and innovations to market. “
For more than 20 years, DaVita has been a leader in creating innovative, patient-centered models of care that use the latest technologies designed to improve quality of life. Drawing on its vast expertise, DVG identifies companies and products for strategic partnerships, venture capital investment opportunities and to incubate transformative solutions. The group focuses on innovation in digital health, pharmaceuticals, medical devices and healthcare delivery models. DVG brings clinical and operational knowledge and seeks to collaborate with other entities to develop, test and commercialize new technologies.
“DaVita Venture Group aims to find new solutions for our patients that go beyond dialysis,” said Steve phillips, vice president of innovation for DVG. “We are delighted to fund selected venture capital investments in start-ups, which will have the potential to drive innovation over time. “
Scaling up patient-centered chronic care requires reinventing healthcare as it exists today. A typical patient with end-stage renal disease is at high risk and high needs. They often have four or more co-morbidities and spend about 11 days in the hospital each year. With a focus on expanding innovation across the continuum, DVG aims to expand access to care and improve clinical outcomes while increasing adoption of value-based care to reduce costs.
“These are exciting times in healthcare as entrepreneurs, researchers and industry leaders envision solutions that could improve the delivery of care,” said Mahesh Krishnan, vice-president of the research and development group for DVG. “We believe that we can contribute to this change and that DaVita Venture Group is a great incubator to help advance these solutions in the market. “
About DaVita Inc.
DaVita (NYSE: DVA) is a healthcare provider focused on transforming the delivery of care to improve the quality of life for patients around the world. The company is one of the largest providers of kidney care services in the United States and has been a leader in clinical quality and innovation for over 20 years. Through DaVita Kidney Care, the company treats patients with chronic kidney disease and end stage renal disease. DaVita is committed to adopting bold, patient-centered care models, implementing the latest technologies and evolving towards integrated care offerings for all. Through these efforts, DaVita has also become the largest home dialysis provider in the country. As of December 31, 2019, DaVita served 206,900 patients in 2,753 outpatient dialysis centers in the United States. The company also operated 259 outpatient dialysis centers in ten countries around the world. DaVita has reduced hospitalizations, improved mortality, and worked collaboratively to propel the kidney care industry to a high-quality, equitable standard of care for all patients, everywhere. To learn more, visit DaVita.com/About.
All statements in this press release, other than statements of historical fact, are forward-looking statements and, as such, are intended to be safe harbor for “forward-looking statements” provided by the Private Securities Litigation Reform. Act of 1995. These forward-looking statements The forward-looking statements are based on DaVita’s current expectations and are based solely on information available as of the date of this press release. DaVita assumes no obligation to publicly update or revise forward-looking statements, whether as a result of changed circumstances, new information, future events or otherwise. Actual future events and results could differ materially from any forward-looking statement because of many factors that involve substantial known and unknown risks and uncertainties. These risks and uncertainties include, without limitation, those described in the risk factors set forth in DaVita Inc.’s annual report on Form 10-K for the year ended December 31, 2019, and the risks and uncertainties discussed in any subsequent reports DaVita files or provides to the Securities and Exchange Commission from time to time.